Surgery Should Complement Endocrine Therapy for Elderly Postmenopausal Women with Hormone Receptor-Positive Early-Stage Breast Cancer

被引:3
|
作者
Nguyen, Olivier [1 ]
Sideris, Lucas [1 ]
Drolet, Pierre [2 ]
Gagnon, Marie-Claude [1 ]
Leblanc, Guy [1 ]
Leclerc, Yves E. [1 ]
Mitchell, Andrew [3 ]
Dube, Pierre [1 ]
机构
[1] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Surg, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada
[2] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Anesthesiol, Montreal, PQ H1T 2M4, Canada
[3] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Pathol, Montreal, PQ H1T 2M4, Canada
关键词
D O I
10.1155/2012/180574
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Endocrine therapy (ET) is an integral part of breast cancer (BC) treatment with surgical resection remaining the cornerstone of curative treatment. The objective of this study is to compare the survival of elderly postmenopausal women with hormone receptor-positive early-stage BC treated with ET alone, without radiation or chemotherapy, versus ET plus surgery. Materials and Methods. This is a retrospective study based on a prospective database. The medical records of postmenopausal BC patients referred to the surgical oncology service of two hospitals during an 8-year period were reviewed. All patients were to receive ET for a minimum of four months before undergoing any surgery. Results. Fifty-one patients were included and divided in two groups, ET alone and ET plus surgery. At last follow-up in exclusive ET patients (n = 28), 39% had stable disease or complete response, 22% had progressive disease, of which 18% died of breast cancer, and 39% died of other causes. In surgical patients (n = 23), 78% were disease-free, 9% died of recurrent breast cancer, and 13% died of other causes. Conclusions. These results suggest that surgical resection is beneficial in this group and should be considered, even for patients previously deemed ineligible for surgery.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer
    Lim, Elgene
    Carson, Emma
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 194 - 195
  • [22] Checkpoint inhibition for early-stage hormone receptor-positive breast cancer
    Schlam, Ilana
    Corti, Chiara
    Sammons, Sarah
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (06) : 511 - 520
  • [23] Adjuvant Endocrine Therapy for Pre-menopausal Women with Hormone Receptor Positive Early-stage Breast Cancer
    Kendall, S.
    Robinson, T.
    Braybrooke, J.
    Strawson-Smith, T.
    CLINICAL ONCOLOGY, 2022, 34 (04) : E179 - E179
  • [24] Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
    Julia Foldi
    Anastasia Tsagianni
    Max Salganik
    Catherine A. Schnabel
    Adam Brufsky
    G. J. van Londen
    Lajos Pusztai
    Tara Sanft
    BMC Cancer, 23
  • [25] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
    Iwata, Hiroji
    BREAST CANCER, 2011, 18 (02) : 92 - 97
  • [26] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
    Hiroji Iwata
    Breast Cancer, 2011, 18 : 92 - 97
  • [27] Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women
    Carleton, Neil
    Nasrazadani, Azadeh
    Gade, Kristine
    Beriwal, Sushil
    Barry, Parul N.
    Brufsky, Adam M.
    Bhargava, Rohit
    Berg, Wendie A.
    Zuley, Margarita L.
    van Londen, G. J.
    Marroquin, Oscar C.
    Thull, Darcy L.
    Mai, Phuong L.
    Diego, Emilia J.
    Lotze, Michael T.
    Oesterreich, Steffi
    McAuliffe, Priscilla F.
    Lee, Adrian, V
    LANCET GLOBAL HEALTH, 2022, 3 (01): : E54 - E66
  • [28] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
    Delea, Thomas E.
    Karnon, Jon
    Sofrygin, Oleg
    Thomas, Simu K.
    Papo, Natalie L.
    Barghout, Victoria
    CLINICAL BREAST CANCER, 2007, 7 (08) : 608 - 618
  • [29] Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer
    Downs-Canner, Stephanie M.
    Gaber, Charles E.
    Louie, Raphael J.
    Strassle, Paula D.
    Gallagher, Kristalyn K.
    Muss, Hyman B.
    Ollila, David W.
    CANCER, 2020, 126 (06) : 1193 - 1201
  • [30] The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer
    Jain, Sarika
    Santa-Maria, Cesar Augusto
    Gradishar, William J.
    ONCOLOGY-NEW YORK, 2015, 29 (07): : 473 - +